- Heat Biologics (NASDAQ:HTBX) rises 14% premarket after completing its gp96-based COVID-19 vaccine cell line ("ZVX-60"), being developed for use as either a standalone, or in combination with other vaccines to enhance prophylactic protection.
- Data, generated at the University of Miami Miller School of Medicine, has confirmed expression of gp96, OX40L and Spike protein.
- Also, preparations for manufacturing the vaccine are well underway.
- https://seekingalpha.com/news/3644813-heat-biologics-soars-14-on-completion-of-zvxminus-60-vaccine-cell-line-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.